KAST, Florian,SCHWILL, Martin,HONEGGER, Annemarie,STÜBER, Jakob,TAMASKOVIC, Rastislav,PLÜCKTHUN, Andreas
申请号：
EPEP2019/077147
公开号：
WO2020/074469A1
申请日:
2019.10.08
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The invention relates to a tetrameric polypeptide comprising a first polypeptide chain comprising a first VL antigen binding domain and a first CL constant domain, a second polypeptide chain comprising a first VH antigen binding domain, a first CH1 constant domain, a first CH2 constant domain and a first CH3 constant domain, a first ligand binding to a HER2 D4 epitope linked to the N-terminus of said first VL antigen binding domain or said first VH antigen binding domain by a first interdomain amino acid linker, a third polypeptide chain comprising a second VL antigen binding domain and a second CL constant domain, a fourth polypeptide chain comprising a second VH antigen binding domain, a second CH1 constant domain, a second CH2 constant domain and a second CH3 constant domain and a third ligand binding to a HER2 D4 epitope linked to the N-terminus of said second VL antigen binding domain or said second VH antigen binding domain by a second interdomain amino acid linker, wherein the VL antigen binding domains and the VH antigen binding domains together constitute a second ligand and a fourth ligand binding to a HER2 D1 epitope. The invention further relates to the tetrameric polypeptide for use in a method for the prevention or treatment of a malignant neoplastic disease, an isolated nucleic acid and a host cell for expression of the polypeptide and a method for obtaining the polypeptide.L'invention concerne un polypeptide tétramère comprenant une première chaîne polypeptidique comprenant un premier domaine de liaison à l'antigène VL et un premier domaine constant CL, une seconde chaîne polypeptidique comprenant un premier domaine de liaison à l'antigène VH, un premier domaine constant CH1, un premier domaine constant CH2 et un premier domaine constant CH3, un premier ligand se liant à un épitope de HER2 D4 lié à l'extrémité N-terminale dudit premier domaine de liaison à l'antigène VL ou dudit premier domaine de liaison d'antigène VH par un premier lieur d'acide am
